- Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial(2022)
Auteurs: Julia Katharina Schwarze, Soizic Garaud, Yanina Jansen, Gil Awada, Valerie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, et al.
- C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting(2021)
Auteurs: Justine Lauwyck, Aline Beckwée, Arno Santens, Julia Katharina Schwarze, Gil Awada, Valerie Vandersleyen, Sandrine Aspeslagh, B Neyns
Pagina's: 371-377
- Acquired epidermodysplasia verruciformis in a patient with human immunodeficiency virus (hiv) infection.(2017)
Auteurs: Annelies Maurits Y Meuwissen, Valerie Vandersleyen, Kaat Wilgenhof, Anita Goossens, Martine Grosber, Lucie Seyler, P Lacor
Pagina's: 54-54
- Vemurafenib-associated Dupuytren- and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients(2016)
Auteurs: Valerie Vandersleyen, Martine Grosber, Sofie Wilgenhof, Joery De Kock, B Neyns, Jan Gutermuth
Pagina's: 1133-1135
- A synopsis of serum biomarkers in cutaneous melanoma patients(2012)
Auteurs: Pierre Vereecken, Frank Cornelis, Nicolas Van Baren, Valerie Vandersleyen, Jean-François Baurain
Pagina's: 260643
